WO2007025540A3 - Substituierte imidazo[1,2b]pyridazine als kinase-inhibitoren, deren herstellung und verwendung als arzneimittel - Google Patents

Substituierte imidazo[1,2b]pyridazine als kinase-inhibitoren, deren herstellung und verwendung als arzneimittel Download PDF

Info

Publication number
WO2007025540A3
WO2007025540A3 PCT/DE2006/001564 DE2006001564W WO2007025540A3 WO 2007025540 A3 WO2007025540 A3 WO 2007025540A3 DE 2006001564 W DE2006001564 W DE 2006001564W WO 2007025540 A3 WO2007025540 A3 WO 2007025540A3
Authority
WO
WIPO (PCT)
Prior art keywords
same
pyridazines
medicaments
production
kinase inhibitors
Prior art date
Application number
PCT/DE2006/001564
Other languages
English (en)
French (fr)
Other versions
WO2007025540A2 (de
Inventor
Olaf Prien
Benjamin Bader
Ulrich Zuegel
Stuart James Ince
Christoph Huwe
Karina Schuck
Knut Eis
Ulrich Luecking
Rolf Jautelat
Judith Guenther
Manfred Husemann
Original Assignee
Schering Ag
Olaf Prien
Benjamin Bader
Ulrich Zuegel
Stuart James Ince
Christoph Huwe
Karina Schuck
Knut Eis
Ulrich Luecking
Rolf Jautelat
Judith Guenther
Manfred Husemann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag, Olaf Prien, Benjamin Bader, Ulrich Zuegel, Stuart James Ince, Christoph Huwe, Karina Schuck, Knut Eis, Ulrich Luecking, Rolf Jautelat, Judith Guenther, Manfred Husemann filed Critical Schering Ag
Priority to CA2620534A priority Critical patent/CA2620534C/en
Priority to EP06775928A priority patent/EP2176266A2/de
Priority to JP2008528339A priority patent/JP5680824B2/ja
Publication of WO2007025540A2 publication Critical patent/WO2007025540A2/de
Publication of WO2007025540A3 publication Critical patent/WO2007025540A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Die Erfindung betrifft neue Inhibitoren für Kinasen, Verfahren zur Herstellung solcher Inhibitoren, Zwischenprodukte zur Herstellung solcher Inhibitoren und Verwendungen solcher Inhibitoren.
PCT/DE2006/001564 2005-09-02 2006-09-01 Substituierte imidazo[1,2b]pyridazine als kinase-inhibitoren, deren herstellung und verwendung als arzneimittel WO2007025540A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA2620534A CA2620534C (en) 2005-09-02 2006-09-01 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
EP06775928A EP2176266A2 (de) 2005-09-02 2006-09-01 Substituierte imidazo[1,2b]pyridazine als kinase-inhibitoren, deren herstellung und verwendung als arzneimittel
JP2008528339A JP5680824B2 (ja) 2005-09-02 2006-09-01 キナーゼ阻害剤としての置換イミダゾ〔１，２ｂ〕ピリダジン、それらの調製及び医薬としての使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005042742A DE102005042742A1 (de) 2005-09-02 2005-09-02 Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE102005042742.1 2005-09-02

Publications (2)

Publication Number Publication Date
WO2007025540A2 WO2007025540A2 (de) 2007-03-08
WO2007025540A3 true WO2007025540A3 (de) 2007-05-18

Family

ID=37709434

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2006/001564 WO2007025540A2 (de) 2005-09-02 2006-09-01 Substituierte imidazo[1,2b]pyridazine als kinase-inhibitoren, deren herstellung und verwendung als arzneimittel

Country Status (5)

Country Link
EP (1) EP2176266A2 (de)
JP (1) JP5680824B2 (de)
CA (1) CA2620534C (de)
DE (1) DE102005042742A1 (de)
WO (1) WO2007025540A2 (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US7989459B2 (en) 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
AR062207A1 (es) 2006-08-04 2008-10-22 Takeda Pharmaceutical Derivados de imidazopiridazina inhibidores de quinasas utiles para prevenir y/o tratar el cancer.
CA2663091A1 (en) * 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Modulators of interleukin-1 receptor-associated kinase
TW200831104A (en) 2006-10-04 2008-08-01 Pharmacopeia Inc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
TW200837064A (en) 2006-10-04 2008-09-16 Pharmacopeia Inc 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
AU2007315234A1 (en) * 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
WO2008058126A2 (en) * 2006-11-06 2008-05-15 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
AR067326A1 (es) * 2007-05-11 2009-10-07 Novartis Ag Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
EP2152708A1 (de) 2007-05-23 2010-02-17 Pharmacopeia, LLC Purinone und 1h-imidazopyridinone als pkc-theta-inhibitoren
FR2918986B1 (fr) 2007-07-19 2009-09-04 Sanofi Aventis Sa Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
EP2217601A1 (de) * 2007-11-08 2010-08-18 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyridazine zur vewendung als proteinkinaseinhibitoren
WO2009062059A2 (en) * 2007-11-08 2009-05-14 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
WO2009140128A2 (en) * 2008-05-13 2009-11-19 Irm Llc Compounds and compositions as kinase inhibitors
JP5503655B2 (ja) 2008-09-22 2014-05-28 アレイ バイオファーマ、インコーポレイテッド Ｔｒｋキナーゼ阻害剤としての置換イミダゾ［１，２ｂ］ピリダジン化合物
JP5600111B2 (ja) 2008-10-22 2014-10-01 アレイ バイオファーマ、インコーポレイテッド ＴＲＫキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピリミジン化合物
FR2939134A1 (fr) * 2008-12-01 2010-06-04 Sanofi Aventis Derives de 6-cycloamino-3-(1h-pyrrolo°2,3-b!pyridin-4-yl) imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique
FR2940284B1 (fr) * 2008-12-19 2011-02-18 Sanofi Aventis Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique
FR2940285A1 (fr) * 2008-12-19 2010-06-25 Sanofi Aventis Derives de 6-cycloamino-2-thienyl-3-(pyridin-4-yl)imidazo °1,2-b!-pyridazine et 6-cycloamino-2-furanyl-3- (pyridin-4-yl)imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique
DE102008062826A1 (de) * 2008-12-23 2010-07-01 Merck Patent Gmbh Pyridazinonderivate
EP2210891A1 (de) * 2009-01-26 2010-07-28 Domain Therapeutics Neue Adenosin-Rezeptorliganden und Verwendungen davon
MX2011009796A (es) * 2009-03-20 2011-12-14 Amgen Inc Inhibidores de la cinasa pi3.
US20120190666A1 (en) * 2009-05-13 2012-07-26 Amgen Inc. Heteroaryl Compounds as PIKK Inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
GB201002911D0 (en) * 2010-02-19 2010-04-07 Medical Res Council Compound
KR101852169B1 (ko) 2010-05-20 2018-04-26 어레이 바이오파마 인크. Trk 키나제 저해제로서의 매크로시클릭 화합물
GB201104669D0 (en) * 2011-03-18 2011-05-04 Medical Res Council Technology Compound
CN103687858B (zh) 2011-05-17 2017-11-21 拜耳知识产权有限责任公司 作为mknk1激酶抑制剂的氨基取代的咪唑并哒嗪
KR101939682B1 (ko) 2011-05-27 2019-01-17 바이엘 인텔렉쳐 프로퍼티 게엠베하 Ｎ-｛3,4-디플루오로-2-〔(2-플루오로-4-요오도페닐)아미노〕-6-메톡시페닐｝-1-[2,3-디하이드록시프로필]사이클로프로판설폰아미드의 키랄 합성
CA2837630A1 (en) 2011-06-01 2012-12-06 Knut Eis Substituted aminoimidazopyridazines
JP5944497B2 (ja) * 2011-06-22 2016-07-05 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ ヘテロシクリルアミノイミダゾピリダジン
SG195100A1 (en) * 2011-07-01 2013-12-30 Bayer Ip Gmbh Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
WO2013009582A1 (en) 2011-07-12 2013-01-17 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
EP3409278B8 (de) 2011-07-21 2020-11-04 Sumitomo Dainippon Pharma Oncology, Inc. Heterocyclische proteinkinase-hemmer
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
CA2849345A1 (en) 2011-09-23 2013-03-28 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
MX342177B (es) * 2011-09-30 2016-09-20 Ipsen Pharma Sas Inhibidores de cinasa 2 de repeticion rica en leucina (lrrk2) macrociclica.
CN103930427B (zh) * 2011-09-30 2016-03-09 昂科迪塞恩股份有限公司 大环flt3激酶抑制剂
ES2576484T3 (es) * 2011-10-20 2016-07-07 Glaxosmithkline Llc Aza-heterociclos bicíclicos sustituidos y análogos como moduladores de sirtuina
ES2650915T3 (es) 2011-12-12 2018-01-23 Bayer Intellectual Property Gmbh Imidazopiridazinas amino-sustituidas
WO2013144189A1 (en) 2012-03-29 2013-10-03 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines
US9409889B2 (en) 2012-04-04 2016-08-09 Bayer Pharma Aktiengesellschaft Amino-substituted imidazopyridazines
WO2013176970A1 (en) 2012-05-22 2013-11-28 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
TWI585088B (zh) 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
EP2920176B1 (de) * 2012-11-19 2017-09-13 Bayer Pharma Aktiengesellschaft Aminoimidazopyridazine als mknk1 kinase hemmstoffe
TWI600654B (zh) 2012-11-19 2017-10-01 艾姆公司 用於治療寄生蟲疾病之化合物及組合物
JP2016506943A (ja) * 2013-01-30 2016-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト Ｍｋｎｋ−１キナーゼ阻害剤としてのアミドイミダゾピリダジン類
US20160287589A1 (en) 2013-02-20 2016-10-06 Bayer Pharma Aktiengesellschaft Substituted-imidazopyridazines
CA2901427A1 (en) 2013-03-07 2014-09-12 Califia Bio, Inc. Mixed lineage kinase inhibitors and method of treatments
CA2913035C (en) 2013-05-20 2017-08-01 University Of Washington Through Its Center For Commercialization 5-aminopyrazole-4-carboxamide inhibitors of cdpk1
WO2015039334A1 (en) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2015039333A1 (en) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
US10214545B2 (en) 2014-01-09 2019-02-26 Bayer Pharma Aktiengesellschaft Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders
WO2015143654A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143652A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143653A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
JP6914834B2 (ja) 2014-11-16 2021-08-04 アレイ バイオファーマ インコーポレイテッド （Ｓ）−Ｎ−（５−（（Ｒ）−２−（２，５−ジフルオロフェニル）−ピロリジン−１−イル）−ピラゾロ［１，５−ａ］ピリミジン−３−イル）−３−ヒドロキシピロリジン−１−カルボキサミド硫酸水素塩の結晶形
WO2016161572A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
AU2016344058A1 (en) 2015-10-26 2018-05-17 Array Biopharma Inc. Point mutations in Trk inhibitor-resistant cancer and methods relating to the same
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
TN2018000335A1 (en) 2016-04-04 2020-01-16 Loxo Oncology Inc Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
PL3800189T3 (pl) 2016-05-18 2023-10-23 Loxo Oncology, Inc. Wytwarzanie (s)-n-(5-((r)-2-(2,5-difluorofenylo)pirolidyn-1-ylo)pirazolo[1,5-a]pirymidyn-3-ylo)-3-hydroksypirolidyno-1-karboksyamidu
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
JP6916562B2 (ja) 2017-08-11 2021-08-11 テリジーン リミテッドＴｅｌｉｇｅｎｅ Ｌｔｄ． 化合物、その薬学的に許容される塩、溶媒和物、立体異性体及び互変異性体、並びに薬物組成物、過剰増殖性障害治療剤、過剰増殖性障害予防剤、薬物、癌治療剤、癌予防剤、及びキナーゼシグナル伝達調節剤
JP7278273B2 (ja) * 2017-10-18 2023-05-19 ブループリント メディシンズ コーポレイション アクチビン受容体様キナーゼの阻害剤としての置換ピロロピリジン
CN110734437B (zh) * 2018-07-19 2022-04-08 南京烁慧医药科技有限公司 吡唑并嘧啶化合物和药物组合物及其应用
CA3127502A1 (en) 2019-02-12 2020-08-20 Sumitomo Dainippon Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
CN111718350B (zh) * 2019-03-19 2021-04-13 华中师范大学 吡唑取代的吡唑并嘧啶化合物和药物组合物及其应用
CN111718351B (zh) * 2019-03-19 2021-10-12 华中师范大学 含氧取代吡唑并嘧啶化合物和药物组合物及其应用
US20220177477A1 (en) * 2019-03-19 2022-06-09 Central China Normal University Pyrazolopyrimidine compound, pharmaceutical composition, and application therefor
CN111718349B (zh) * 2019-03-19 2021-11-02 华中师范大学 含氟吡唑并嘧啶化合物和药物组合物及其应用
KR20220007111A (ko) * 2019-05-08 2022-01-18 티와이케이 메디슨즈, 인코포레이티드 키나아제 억제제로 사용되는 화합물 및 이의 응용
CN114437077B (zh) * 2020-11-04 2024-01-30 浙江同源康医药股份有限公司 用作激酶抑制剂的化合物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064674A1 (en) * 2000-03-01 2001-09-07 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
WO2002066481A1 (en) * 2001-02-17 2002-08-29 Astrazeneca Ab Pyrimidine derivatives for inhibition of cell-proliferation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3542661A1 (de) * 1985-12-03 1987-06-04 Bayer Ag Imidazopyridazinalkensaeureamide, verfahren zu ihrer herstellung, zwischenprodukte zu ihrer herstellung
WO1998049167A1 (en) * 1997-04-25 1998-11-05 Takeda Chemical Industries, Ltd. Condensed pyridazine derivatives, their production and use
SE9800835D0 (sv) * 1998-03-13 1998-03-13 Astra Ab New Compounds
PL354241A1 (en) * 1999-09-17 2003-12-29 Abbott Gmbh & Co.Kgabbott Gmbh & Co.Kg Kinase inhibitors as therapeutic agents
KR101075812B1 (ko) * 2002-12-18 2011-10-25 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서의 트리아졸로피리다진
DE602004006536T2 (de) * 2003-12-31 2008-01-31 Schering-Plough Ltd. Bekämpfng von parasiten in tieren durch anwendung von imidazoä1,2-büpyridazinderivaten
WO2007013673A1 (en) * 2005-07-29 2007-02-01 Astellas Pharma Inc. Fused heterocycles as lck inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064674A1 (en) * 2000-03-01 2001-09-07 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
WO2002066481A1 (en) * 2001-02-17 2002-08-29 Astrazeneca Ab Pyrimidine derivatives for inhibition of cell-proliferation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BULLOCK A N ET AL: "Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in Moloney Murine Leukemia Virus (PIM-1) Kinase", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 48, no. 24, 27 October 2005 (2005-10-27), pages 7604 - 7614, XP002405453, ISSN: 0022-2623 *
KATE F. BYTH ET AL.: "imidazo(1,2-b)pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, pages 2249 - 2252, XP002420105 *
See also references of EP2176266A2 *

Also Published As

Publication number Publication date
JP2009506993A (ja) 2009-02-19
CA2620534A1 (en) 2007-03-08
DE102005042742A1 (de) 2007-03-08
WO2007025540A2 (de) 2007-03-08
CA2620534C (en) 2014-05-27
JP5680824B2 (ja) 2015-03-04
EP2176266A2 (de) 2010-04-21

Similar Documents

Publication Publication Date Title
WO2007025540A3 (de) Substituierte imidazo[1,2b]pyridazine als kinase-inhibitoren, deren herstellung und verwendung als arzneimittel
WO2008046581A3 (de) Substituierte tetrahydropyrrolopyrazin-verbindungen als inhibitoren der monoaminwiederaufnahme und deren verwendung in arzeimitteln
WO2005037198A3 (en) Preparation of 1,7-disubstituted azabenzimidazoles as kinase inhibitors
WO2006021379A8 (de) Dihydropteridinonderivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
WO2006021378A8 (de) Dihydropteridinonderivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
WO2007065664A3 (en) Pyrazolo[1,5-a]pyridine-3-carboxylic acids as ephb and vegfr2 kinase inhibitors
WO2008121687A3 (en) Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
WO2007117995A3 (en) Kinase inhibitors
WO2007000325A3 (de) Substituierte 1-oxa-3,8-diazaspiro[4.5]-decan-2-on-verbindungen und deren verwendung zur herstellung von arzneimitteln
WO2008009415A3 (de) 4-heteroaryl-substituierte 1-aminocyclohexan-1- und cyclohexen-1-derivate mit wirkung auf das opiod rezeptor system
WO2007095188A3 (en) Dihydrodiazepines useful as inhibitors of protein kinases
WO2004112719A3 (en) Chemical compounds
WO2007095223A3 (en) Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases
WO2007104034A3 (en) Glucokinase activators
WO2007056164A3 (en) Aminopyrimidines useful as kinase inhibitors
WO2006032342A3 (de) Arzneimittel enthaltend carbonylverbindungen sowie deren verwendung
MY152283A (en) Polo-like kinase inhibitirs
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
WO2007067506A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
WO2007058850A3 (en) Inhibitors of akt activity
WO2007022384A3 (en) Pyrazine kinase inhibitors
WO2008113469A3 (de) Substituierte imidazo- und triazolopyrimidine
WO2007015923A8 (en) Benzimidazoles useful as inhibitors of protein kinases
WO2006076442A3 (en) Triazolopyrimidine derivatives
WO2008079521A3 (en) Tricyclic heteroaryl compounds useful as inhibitors of janus kinase

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006775928

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2620534

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008528339

Country of ref document: JP